Pfizer's stock has risen off its lows, but remains 50% below its 2021 highs.

Pfizer has fallen behind the pack when it comes to GLP-1 drugs, but the company is still fighting.

By Yadarisa Shabong Jan 20 (Reuters) - Britain's GSK and Japan's Shionogi said on Tuesday that Pfizer will exit their HIV ...

Pfizer is one of the world's largest and oldest drug companies. Thanks to its Covid vaccine, shares rose dramatically during the pandemic. Now that the stock has sharply corrected, long-term investors ...

Pfizer is one of the largest pharmaceutical companies on the planet. It has a proven track record of finding, developing, and commercializing new drugs. The recent price advance is worth paying ...

Pfizer's third-quarter sales fell 6% year over year to $16.65 billion, beating the consensus of $16.59 billion. The revenue reflected an operational decline of 7%. The operational decrease was ...